Biohaven And Yale Win $4M Judgment Against Avilar And RA Capital Over Willful Misappropriation Of Yale Trade Secret

Why Biohaven Stock Was Rocking the Market This Week

Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.

Why Is Biohaven Stock Soaring Wednesday?

Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.

Biohaven shares are trading higher after the company announced that the U.S. District Court for the District of Delaware ruled in its favor in the case against Avilar Therapeutics. Biohaven announced a collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to the company's Kv7 ion channel platform.

8-K filing — Biohaven Ltd. (BHVN)

Filed: 2026-08-26 AccNo: 0001935979-26-000072 Size: 890 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits